Synonyms: MCI-186 | MCI186 | Radicava® | Radicut®
Compound class:
Synthetic organic
Comment: Edaravone (MCI-186) is a free radical scavenger [1]. It is used clinically for its neuroprotective action.
|
|
No information available. |
Summary of Clinical Use |
Edaravone has been used to treat stroke patients in Japan since 2001 [4-5]. It has since been approved as a therapy for amyotrophic lateral sclerosis (ALS) [2,6] (Japan approval in 2015, FDA approval in 2017). In the EU it can be used for this indication in accordance with orphan drug designation status. Edaravone is most effective in patients in early-stage ALS. Formulations are available for i.v. infusion and oral administration. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT00821821 | Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke | Phase 2 Interventional | Mitsubishi Tanabe Pharma Corporation | 3 |
External links |
For extended ADME data see the following: Drugs.com |